Keshava Kumar

1.2k total citations
26 papers, 604 citations indexed

About

Keshava Kumar is a scholar working on Hematology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Keshava Kumar has authored 26 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 10 papers in Infectious Diseases and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Keshava Kumar's work include Acute Myeloid Leukemia Research (15 papers), Parasitic Diseases Research and Treatment (9 papers) and Neutropenia and Cancer Infections (5 papers). Keshava Kumar is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Parasitic Diseases Research and Treatment (9 papers) and Neutropenia and Cancer Infections (5 papers). Keshava Kumar collaborates with scholars based in United States, India and France. Keshava Kumar's co-authors include K. D. Ramaiah, K. Ramu, Pradeep Das, P. K. Das, Helen Guyatt, J. Curtis Nickel, S P Pani, Philip M. Hanno, Heather Thomas and Barry Skikne and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Keshava Kumar

26 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keshava Kumar United States	14	363	216	175	149	113	26	604
Charles Mackenzie United States	15	497 1.4×	353 1.6×	348 2.0×	215 1.4×	34 0.3×	42	922
Daniel J. Tisch United States	14	475 1.3×	313 1.4×	183 1.0×	248 1.7×	16 0.1×	19	682
Virgínia Velasco-Tirado Spain	15	207 0.6×	225 1.0×	68 0.4×	106 0.7×	5 0.0×	52	621
Blanca Jarilla Philippines	14	55 0.2×	478 2.2×	152 0.9×	258 1.7×	20 0.2×	33	651
Masaaki Shimada Japan	16	89 0.2×	188 0.9×	83 0.5×	104 0.7×	9 0.1×	86	707
Charlotte Boullé France	10	290 0.8×	148 0.7×	128 0.7×	126 0.8×	2 0.0×	20	462
Michael Kalnoky United States	13	141 0.4×	63 0.3×	103 0.6×	52 0.3×	20 0.2×	21	447
Sonalika Kar India	10	189 0.5×	138 0.6×	162 0.9×	59 0.4×	8 0.1×	18	358
Marie‐Catherine Receveur France	13	282 0.8×	84 0.4×	374 2.1×	33 0.2×	65 0.6×	27	533
Marija Stojković Germany	16	370 1.0×	306 1.4×	36 0.2×	103 0.7×	3 0.0×	35	951

Countries citing papers authored by Keshava Kumar

Since Specialization

Citations

This map shows the geographic impact of Keshava Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keshava Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keshava Kumar more than expected).

Fields of papers citing papers by Keshava Kumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keshava Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keshava Kumar. The network helps show where Keshava Kumar may publish in the future.

Co-authorship network of co-authors of Keshava Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Keshava Kumar. A scholar is included among the top collaborators of Keshava Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keshava Kumar. Keshava Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravandi, Farhad, Andrew H. Wei, Hartmut Döhner, et al.. (2020). CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial.. Journal of Clinical Oncology. 38(15_suppl). 7530–7530. 1 indexed citations

Wei, Andrew H., Gail J. Roboz, Hervé Dombret, et al.. (2020). CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial. Blood. 136(Supplement 1). 38–40. 6 indexed citations

Olíva, Esther Natalie, Suman Kambhampati, Albert Oriol, et al.. (2020). CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial. Blood. 136(Supplement 1). 14–15. 7 indexed citations

Ravandi, Farhad, Christopher Pocock, Dominik Selleslag, et al.. (2020). AML-186: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial. Clinical Lymphoma Myeloma & Leukemia. 20. S187–S188. 1 indexed citations

Roboz, Gail J., Farhad Ravandi, Andrew H. Wei, et al.. (2020). CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial. Blood. 136(Supplement 1). 32–33. 13 indexed citations

Döhner, Hartmut, Andrew H. Wei, Pau Montesinos, et al.. (2020). Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.. Journal of Clinical Oncology. 38(15_suppl). 7513–7513. 2 indexed citations

Garcia‐Manero, Guillermo, Bart L. Scott, Christopher R. Cogle, et al.. (2018). CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research. 72. 79–85. 15 indexed citations

Garcia‐Manero, Guillermo, Michael R. Savona, Steven D. Gore, et al.. (2016). CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Blood. 128(22). 905–905. 5 indexed citations

Laille, Eric, Tao Shi, Guillermo Garcia‐Manero, et al.. (2015). Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE. 10(8). e0135520–e0135520. 48 indexed citations

10.

Nickel, J. Curtis, Philip M. Hanno, Keshava Kumar, & Heather Thomas. (2012). Second Multicenter, Randomized, Double-blind, Parallel-group Evaluation of Effectiveness and Safety of Intravesical Sodium Chondroitin Sulfate Compared With Inactive Vehicle Control in Subjects With Interstitial Cystitis/Bladder Pain Syndrome. Urology. 79(6). 1220–1225. 52 indexed citations

11.

Kumar, Keshava & K. D. Ramaiah. (2008). Usage of personal-protection measures against mosquitoes and the low prevalences ofWuchereria bancroftimicrofilaraemia in the Indian city of Chennai. Annals of Tropical Medicine and Parasitology. 102(5). 391–397. 13 indexed citations

12.

Ramaiah, K. D., et al.. (2006). A campaign of 'communication for behavioural impact' to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage. Annals of Tropical Medicine and Parasitology. 100(4). 345–361. 24 indexed citations

13.

Ramaiah, K. D., et al.. (2005). Situation analysis in a large urban area of India, prior to launching a programme of mass drug administrations to eliminate lymphatic filariasis. Annals of Tropical Medicine and Parasitology. 99(3). 243–252. 22 indexed citations

14.

Ramaiah, K. D., et al.. (2003). The mosquito problem and type and costs of personal protection measures used in rural and urban communities in Pondicherry region, South India. Acta Tropica. 88(1). 3–9. 37 indexed citations

15.

Ramaiah, K. D., et al.. (2001). Effectiveness of community and health services‐organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Tropical Medicine & International Health. 6(12). 1062–1069. 45 indexed citations

16.

Ramaiah, K. D., et al.. (2000). A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single‐dose DEC mass treatment and some related operational aspects. Tropical Medicine & International Health. 5(12). 842–847. 94 indexed citations

17.

Ramaiah, K. D. & Keshava Kumar. (2000). Effect of lymphatic filariasis on school children. Acta Tropica. 76(2). 197–199. 22 indexed citations

18.

Ramaiah, K. D., Keshava Kumar, K. Ramu, S P Pani, & Pradeep Das. (1997). Functional impairment caused by lymphatic filariasis in rural areas of South India. Tropical Medicine & International Health. 2(9). 832–838. 67 indexed citations

19.

Ramaiah, K. D., Keshava Kumar, & K. Ramu. (1996). Knowledge and beliefs about transmission, prevention and control of lymphatic filariasis in rural areas of South India. Tropical Medicine & International Health. 1(4). 433–438. 50 indexed citations

20.

Ramaiah, K. D., K. Ramu, Keshava Kumar, & Helen Guyatt. (1996). Epidemiology of acute filarial episodes caused by Wuchereria bancrofti infection in two rural villages in Tamil Nadu, south India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 90(6). 639–643. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact